Anivovetmab

• CAT Number: I042176
• CAS Number: 2370896-63-0
• Purity: ≥95%

Anivovetmab（Cat No.:I042176）is an investigational monoclonal antibody designed to target and neutralize the spike protein of the SARS-CoV-2 virus, which causes COVID-19. By binding to the spike protein, anivovetmab prevents the virus from entering human cells and replicating. It is part of a class of monoclonal antibodies being developed as potential treatments for COVID-19, especially in patients with mild to moderate disease who are at high risk of progression. Clinical trials are evaluating anivovetmab’s safety, efficacy, and potential to reduce the severity and duration of COVID-19 symptoms in affected individuals.